Page 4 - 51 the significance--29.2_opt
P. 4

1. T2DM: an introduction







          Professor Michael Nauck            Professor Ele Ferrannini
          Diabeteszentrum Bad Lauterberg     Department of Internal Medicine
          Bad Lauterberg im Harz, Germany    University of Pisa School of Medicine
                                             Pisa, Italy

          What is T2DM?

          Definition and diagnosis


          Type 2 diabetes mellitus (T2DM) is a chronic, progressive disease,  char-
                                                                       1
          acterised by hyperglycaemia. Insulin resistance (i.e., a reduced cellular
          response  to  the  hormone)   and  impaired  pancreatic  β-cell  function
                                    2
          are the chief pathogenetic mechanisms.  They often occur in concert,
                                                 3
          resulting in over-production of glucose from the liver, diminished glucose
          uptake  in  tissues  throughout  the  body,  and  consequently  a  net  in-
          crease in blood glucose levels.

          Simple blood tests allow for the diagnosis of T2DM as well as predia-
          betes, which is a condition of milder dysglycaemia at high risk of pro-
          gressing to overt T2DM. The criteria for the diagnosis of prediabetes and
          diabetes are presented in Table 1 and 2.



          Table 1. WHO and ADA criteria for the diagnosis of prediabetes

                           Criteria for the diagnosis of prediabetes

           Fasting plasma        110 to 125 mg/dL (6.1 mmol/l to 6.9 mmol/l) (WHO)
           glucose (FPG)  (4, 5)  100 to 125 mg/dL (5.6 mmol/l to 6.9 mmol/l) (ADA)
                                           or

           Post-prandial glucose   140 to 199 mg/dL (7.8 mmol/l to 11.0 mmol/l)
           (PPG) a (5)
                                           or

           HbA 1c b (5)          5.7–6.4%


          a   Defined using the 2h oral glucose tolerance test (OGTT) after ingesting the 75g glucose load. 4
          b   The  test  should  be  performed  in  a  laboratory  using  a  method  that  is  NGSP  certified  and
            standardised to the DCCT assay.  IFG and IGT represent intermediate states of abnormal
                                    5
            glucose regulation that exist between normal glucose homeostasis and diabetes.  Impaired
                                                                      6
            fasting glucose (IFG) is now defined by an elevated fasting plasma glucose (FPG) concentration
            (≥100 and <126 mg/dl; ≥5.6 and <7 mmol/l).  Impaired glucose tolerance (IGT) is defined by an
                                          7
            elevated 2-h plasma glucose concentration (≥140 and <200 mg/dl; ≥7.8 and <11.1 mmol/l)
            after a 75-g glucose load on the oral glucose tolerance test (OGTT) in the presence of an FPG
            concentration <126 mg/dl. 7 8
                                           4
   1   2   3   4   5   6   7   8   9